Journal article

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer

H Moon, CS Lee, KL Inder, S Sharma, E Choi, DM Black, K-A Le Cao, C Winterford, JI Coward, MT Ling, DJ Craik, RG Parton, PJ Russell, MM Hill



Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carci..

View full abstract

University of Melbourne Researchers


Awarded by National Health and Medical Research Council of Australia

Awarded by NHMRC Project

Awarded by NHMRC Australia Fellowship

Awarded by NHMRC Enabling

Awarded by Worldwide Cancer Research

Funding Acknowledgements

S. We thank Duka Skalamera and Mareike Dahmer of the UQDI ARVEC facility for producing lentivirus, and the participants who kindly donated tissues to the Australian Prostate Cancer BioResource. This work was supported by project grants from the Association for International Cancer Research and Prostate Cancer Foundation Australia. MMH received a Career Development Award from the National Health and Medical Research Council of Australia (no. 569512). RGP was supported by NHMRC Project Grant 631371 and an NHMRC Australia Fellowship (569452). HM is supported by University of Queensland International Postgraduate Research Scholarship. The Australian Prostate Cancer BioResource is supported by an NHMRC Enabling Grant (no. 614296) and by an infrastructure grant from the Prostate Cancer Foundation of Australia. The ARVEC facility received support from the Australian Cancer Research Foundation.